axm221

Alana M. Murphy, MD

Contact Dr. Murphy

1025 Walnut Street
Suite 1100
Philadelphia, PA 19107

(215) 955-6961
(215) 923-1884 fax

Most Recent Peer-reviewed Publications

  1. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer
  2. Endoscopic management of vesicoueteral reflux in adult women
  3. Nonseminomatous Germ Cell Tumor
  4. Overnight urethral stenting after tubularized urethroplasty for distal hypospadias
  5. The clinical utility and safety of the endoscopic treatment of vesicoureteral reflux in patients with duplex ureters
  6. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy
  7. Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non-muscle-invasive Bladder Cancer Refractory to Standard Intravesical Therapy
  8. Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor
  9. Increasing Detection Rate of Benign Renal Tumors: Evaluation of Factors Predicting for Benign Tumor Histologic Features During Past Two Decades
  10. Gender discrepancies in the diagnosis of renal cortical tumors
  11. Reevaluation of TNM staging of renal cortical tumors: Recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent
  12. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy
  13. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger
  14. Failure of the AmbicorĀ® inflatable penile prosthesis to deflate
  15. Cryosurgical ablation of the prostate: High-risk patient outcomes
  16. Re-evaluation of the tumour-node-metastasis staging of locally advanced renal cortical tumours: Absolute size (T2) is more significant than renal capsular invasion (T3a)
  17. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival
  18. Controversies in prostate cancer screening